Eisai's Access Engine: IQLIK Launch Meets the First-Ever Quarterly Commercial Profit
LEQEMBI's subcutaneous auto-injector and a leaner cost base flipped Eisai's flagship to a quarterly commercial profit — and its Kisunla-conversion angle now targets a rival's dropout patients.
ESALY · Earnings Call · 2026-08-03
The fork in the access road
Eisai's Q1 FY2026 call is a story about removing friction from the most important asset it owns. LEQEMBI grew 27% year-on-year to JPY 29.3 billion (and a cleaner 64% ex the Chinese distributor stockpiling that flattered the prior-year base), but the real headline is the July 13 U.S. approval of LEQEMBI IQLIK, the subcutaneous auto-injector, for initiation treatment, with commercial launch timed for late August. Management framed this as an access engine, not a formulation tweak: “with this approval, from the start of the treatment, patients are able to choose from IV or IQLIK. From the initiation therapy to maintenance treatment, treatment options can be offered based on patient circumstances.” — Haruo Naito, COO · 2026-08-03 The pricing construct is deliberately engineered to be P&L- and patient-neutral: WAC of $385 per 250-mg vial — roughly double the maintenance price — is set so that total medical cost lands at parity with IV, with home administration capturing the convenience surplus. On reimbursement, Eisai expects IQLIK initiation to piggyback on the medical-exception scheme already covering maintenance, with Medicare Part D formulary listing to follow in 2027. This is the same access runway the company flagged a year ago, when the SC formulation's Part B-to-D transition was pegged as the gate to scale — the new element is that insurance and access now have a tangible product to attach to. The global keyword trajectory had already clocked initiation therapy as a theme worth watching since Q4 2025, and this quarter's approval is the payoff.The P&L finally bends
The access story matters more because the economics are inflecting. Revenue rose 15.6% to JPY 234.3 billion and operating profit rose 19.2% to JPY 24.7 billion, with the cost-of-sales ratio held at 21.8% as LEQEMBI, DAYVIGO and LENVIMA each saw unit costs fall. CFO Oyama made the milestone explicit:That profit arrived even as R&D (+12.7%) and SG&A (+14.6%) both rose — the discipline came from mix and manufacturing, not from starving the pipeline. The growth is increasingly a mix story: LENVIMA led in absolute terms at JPY 97.3 billion (+16%), but DAYVIGO grew fastest at +38% to JPY 18.9 billion, confirming the orexin franchise's global lift. A weak yen added roughly JPY 18.9 billion to revenue, yet CFO Oyama stressed that “the impact on the operating profit was limited” — Takuya Oyama, CFO · 2026-08-03 (just JPY 1.38 billion) — the margin improvement is operational, not FX cosmetics. That distinction matters because analysts in the prior year repeatedly pushed on gross-margin softness; this quarter the same analysts (Yamaguchi, Hashiguchi) instead pressed on whether the cost-of-sales beat was sustainable. Management's answer — continued LEQEMBI/DAYVIGO unit-cost declines plus low-cost LENVIMA mix — is the most encouraging iteration of that claim to date.while we had planned to achieve profitability on a commercial basis this fiscal year, excluding LEQEMBI's R&D expenses, we posted our first-ever profit in the first quarter, thanks to LEQEMBI's strong growth, ongoing cost control and the prioritized allocation of SG&A expenses to key markets.
Converting the franchise — and reloading the pipeline
The freshest competitive angle is Kisunla conversion. A Macquarie analyst asked directly whether Eisai is converting Eli Lilly's fixed-duration patients who stop Kisunla only to worry about plaque resurgence. The answer was unequivocal:This "stay on treatment" argument is Eisai's core differentiator, restated across quarters. A year ago, Haruna leaned on durability: “LEQEMBI has a long-term experience... I think this is a compelling reason for LEQEMBI to be chosen.” — Katsuya Haruna, Head of US Business · 2025-05-15 The LEADER registry data — 86.6% retention, 82.5% of staged patients stable or improved, no macrohemorrhages or treatment-related deaths — now give that talking point a quantitative backbone, and the IQLIK launch gives physicians a logistical reason to start earlier and stay longer. Blood-based biomarkers are doing the funnel work on the diagnosis side: U.S. BBM test volume grew 75% year-on-year, and BBM's share of A-beta confirmatory testing is expected to jump from 15% to roughly 50% by FY2028. That is the patient funnel Eisai is pouring into, and it is largely company-unique rather than sector boilerplate. The pipeline bridge is also loading. The anti-MTBR tau program etalanetug showed proof of mechanism (62–89% reductions in eMTBR-tau243), and together with the A-T-N continuum it forms the backbone of the medium-term story, with sporadic-AD top-line data due FY2027 and the preclinical AHEAD 3-45 readout in FY2028 — the same study Dr. Kramer defended a year ago: “our AHEAD 3-45 trial... can truly evaluate preclinical AD.” — Lynn D. Kramer, Chief Clinical Officer · 2025-08-05 Meanwhile ledasorexton, the orexin-2 receptor agonist, reads out Phase II before the fiscal year ends — a space where fellow reporter Takeda's parallel orexin agonist programs confirm the platform is a sunrise theme, not a solo bet. The tau pathology data, the BBM funnel, and the IQLIK launch collectively answer the question investors have posed for years: can LEQEMBI become a durable, profitable franchise rather than a chronic launch-in-progress? Q1's first-ever commercial-base profit is the strongest signal yet that the answer is yes — though the risk, as ever, is execution at the reimbursement and conversion layer, precisely where Eisai has historically under-delivered versus expectation.According to the label from IV to IQLIK conversion is possible. And similarly, patients who stopped the treatment of Kisunla, it is possible to transition or convert to LEQEMBI. And in actual clinical practice, we are seeing such conversions.